Autolus Therapeutics (AUTL) Total Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Total Liabilities for 9 consecutive years, with $410.9 million the latest figure, recorded in Q4 2025.

• Quarterly Total Liabilities rose 15.63% year-over-year to $410.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $410.9 million (up 15.63% YoY) and the FY2025 annual result came in at $410.9 million, up 15.63% from the prior year.
• Total Liabilities grew to $410.9 million in Q4 2025 per AUTL's latest filing, from $396.5 million in the prior quarter.
• Over the last five years, Total Liabilities for AUTL reached as high as $410.9 million in Q4 2025 and fell as low as $47.0 million in Q2 2021.
• A 5-year average of $227.0 million and a median of $223.6 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2021 — Total Liabilities tumbled 35.33% — and 2023, when it surged 122.87%.
• Year by year, Total Liabilities stood at $92.2 million in 2021, then soared by 107.72% to $191.6 million in 2022, then surged by 37.74% to $263.9 million in 2023, then jumped by 34.67% to $355.4 million in 2024, then grew by 15.63% to $410.9 million in 2025.
• According to Business Quant data, Total Liabilities over the past three periods registered $410.9 million, $396.5 million, and $374.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.